Research programme: oncolytic virus - TILT Biotherapeutics

Drug Profile

Research programme: oncolytic virus - TILT Biotherapeutics

Alternative Names: Ad5/3-E2F-d24-hTNFa-IRES-hIL2; Adv-5/3-d24-TNF-IL2; O-Ad; TILT-123; TILT-234; TILT-321

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TILT Biotherapeutics
  • Class Antineoplastics; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Sep 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (AACR-2017)
  • 06 Sep 2017 Pharmacodynamics data from preclinical studies in Cancer presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR - 2017)
  • 14 Dec 2016 TILT Biotherapeutics plans a phase I trial for Malignant melanoma in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top